Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer

BMC Cancer

Ga-Eon Kim³  Ji Shin Lee³  Yoo-Duk Choi³  Kyung-Hwa Lee³  Jae Hyuk Lee³  Jong Hee Nam³  Chan Choi³  Sung Sun Kim³  Min Ho Park¹  Jung Han Yoon¹  Sun-Seog Kweon² 

[1] Department of Surgery, Chonnam National University Medical School, Gwangju, Republic of Korea

[2] Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea

[3] Deparment of Pathology, Chonnam National University Medical School, Gwangju, Republic of Korea

关键词: Tissue inhibitor of metalloproteinase;    Matrix metalloproteinase;    Immunohistochemistry;    Molecular subtype;    Breast cancer;   

Others  :  1117873
DOI  :  10.1186/1471-2407-14-959

 received in 2014-03-28, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

Metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) are involved in several key pathways of tumor growth, invasion and metastasis, but little is known about their expression according to different molecular subtypes of breast cancer. The aims of this study were to assess the prevalence and clinical significance of MMP and TIMP expression in invasive breast cancer and to determine its association with immunohistochemical-based molecular classification.

Methods

Tissue microarray sections were immunostained for estrogen receptor-α (ER-α), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), cytokeratin (CK) 5/6, epidermal growth factor receptor (EGFR) and with specific antibodies against MMP-1, 2, 7, 9, 11, 13, and 14 and TIMP-1, 2, and 3. Based on the immunostaining data from five of the markers used (ER-α, PR, HER2, EGFR and CK5/6), three major subtypes (123 luminal A, 31 basal-like, and 17 HER2-overexpressing) were selected.

Results

Statistically significant differences in the expression of MMPs and TIMPs among the three subtypes were found in tumoral MMP7 (P = 0.005), tumoral MMP-9 (P = 0.000), tumoral MMP-13 (P = 0.016) and stromal MMP-13 (P = 0.016). The incidence of tumoral MMP-9 expression in the HER2-overexpressing subtype was significantly higher than in the luminal A subtype (P = 0.021). Tumoral MMP-9 and stromal MMP-13 expression were significantly higher in the HER2-overexpressing subtype than in the basal-like subtype (P = 0.000 and P = 0.016, respectively). Tumoral MMP-7 expression was significantly higher in the basal-like subtype compared to luminal A (P = 0.007) and HER2-overexpressing subtype (P = 0.004). Tumoral MMP-13 showed a higher expression in the basal-like subtype than in the HER2-overexpressing subtype (P = 0.010). In multivariate analysis, stage and stromal MMP-1 expression were significantly related to overall survival. Stage was of independent prognostic significance for disease-free survival.

Conclusion

We found some variations in MMP and TIMP expression among the immunohistochemical-based molecular subtypes of breast carcinomas, suggesting differences in their tumor pathophysiology. Additional studies are needed to determine the mechanisms underlying the differences of MMP and TIMP expression in the molecular subtypes for the development of specific therapeutic targets for breast cancer subtypes.

【 授权许可】

   
2014 Kim et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ko SS: Korean Breast Cancer Society: Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996–2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 2008, 98:318-323.
• [2]Reis-Filho JS, Lakhani SR: Breast cancer special types: why bother? J Pathol 2008, 216:394-398.
• [3]Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
• [4]Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffery SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
• [5]Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
• [6]Sotiriou C, Neo SY, McShane LM, EL K, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100:10393-10398.
• [7]van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
• [8]Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
• [9]Marotti JD, Collins LC, Hu R, Tamimi RM: Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2010, 23:197-204.
• [10]Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol 2008, 226:2568-2581.
• [11]Vu TH, Werb Z: Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000, 14:2123-2133.
• [12]Fassina G, Ferrari N, Brigati C, Benelli R, Santi L, Noonan DM, Albini A: Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis 2000, 18:111-120.
• [13]Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252.
• [14]Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34.
• [15]Fingleton B: Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007, 13:333-346.
• [16]Vizoso FJ, González LO, Corte MD, Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM, García-Muñiz JL: Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007, 96:903-911.
• [17]McGowan PM, Duffy MJ: Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008, 19:1566-1572.
• [18]Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC: Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009, 9:20. BioMed Central Full Text
• [19]González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ: Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol 2009, 40:1224-1233.
• [20]Bae YK, Gong GY, Kang J, Lee AW, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH, The Breast Pathology Study Group of Korean Society of Pathologists: HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer. J Breast Cancer 2012, 15:381-387.
• [21]Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
• [22]Tang P, Skinner KA, Hicks DG: Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009, 18:125-132.
• [23]Wang Y, Zhe H, Ding Z, GAo P, Zhang N, Li G: Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg 2012, 36:1189-1194.
• [24]Moreno-Bueno G, Salvador F, Martín A, Floristán A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA, Rojo-Sebastián A, Martínez A, Hardisson D, Csiszar K, Portillo F, Peinado H, Palacios J, Cano A: Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med 2011, 3:528-544.
• [25]Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, Walter MA, Martens JW, Richardson AL, Giuliano AE, Cui X: FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 2010, 70:3870-3876.
• [26]Allen MD, Vaziri R, Green M, Chelala C, Brentnall AR, Dreger S, Vallath S, Nitch-Smith H, Hayward J, Carpenter R, Holliday DL, Walker RA, Hart IR, Jones JL: Clinical and functional significance of α9β1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol 2011, 223:646-658.
• [27]Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F: Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 2010, 56:860-867.
• [28]Lee JS, Fackler MJ, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Sukumar S: Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther 2010, 9:1017-1024.
• [29]Jones JL, Walker RA: Control of matrix metalloproteinase activity in cancer. J Pathol 1997, 183:377-379.
• [30]Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
• [31]Sullu Y, Demirag GG, Yildirim A, Karagoz F, Kandemir B: Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract 2011, 207:747-753.
• [32]Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10:7621-7628.
• [33]Fatunmbi M, Shelton J, Aronica SM: MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC). Breast Cancer Res Treat 2012, 135:519-530.
• [34]Freije JM, Díez-Itza I, Balbín M, Sánchez LM, Blasco R, Tolivia J, López-Otín C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994, 269:16766-16773.
• [35]Leeman MF, Curran S, Murray GI: The structure, regulation, and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002, 37:149-166.
• [36]Knäuper V, Smith B, López-Otin C, Murphy G: Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem 1997, 248:369-373.
• [37]Pivetta E, Scapolan M, Pecolo M, Wassermann B, Abu-Rumeileh I, Balestreri L, Borsatti E, Tripodo C, Colombatti A, Spessotto P: MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res 2011, 13:R105. BioMed Central Full Text
• [38]Ibaragi S, Shimo T, Hassan NM, Isowa S, Kurio N, Mandai H, Kodama S, Sasaki A: Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin α1β1 and α2β1-p38 MAPK signaling. Anticancer Res 2011, 31:1307-1313.
• [39]Morrison C, Mancini S, Cipollone J, Kappelhoff R, Roskelley C, Overall C: Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J Biol Chem 2011, 286:34271-34285.
• [40]Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK: Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res 2010, 70:3494-3504.
• [41]Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y, Niu R, Sun B, Hao X: Tumor-derived matrix metalloproteinase -13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008, 8:83. BioMed Central Full Text
• [42]Zhang B, Liu YX, Cao WF, Cao XC, Ning LS, Hao XS: Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer. Zhonghua Bing Li Xue Za Zhi 2008, 37:471-476.
• [43]Wang F, Reierstad S, Fishman DA: Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 2006, 236:292-301.
• [44]Mylona E, Magkou C, Ciannopoulou I, Agrogiannis G, Markaki S, Keramopoulos A, Nakopoulou L: Exprression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome. Breast Cancer Res 2006, 8:R57. BioMed Central Full Text
• [45]Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, Sweep CG: Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol 2004, 202:395-402.
• [46]del Casar JM, Carreño G, González LO, Junquera S, González-Reyes S, González JM, Bongera M, Merino AM, Vizoso FJ: Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer. J Cancer Res Clin Oncol 2010, 136:1049-1058.
• [47]Jiang X, Huang X, Li J, Shi Y, Zhou L: Relationship between tissue inhibitors of metalloproteinase and metastasis and prognosis in breast cancer. Zhonghua Wai Ke Za Zhi 2000, 38:291-293. 19
• [48]Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J: Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006, 95:65-72.